title: Chalcone derivatives antagonize interactions between the human oncoprotein MDM2 and p53.
abstract: The oncoprotein MDM2 inhibits the tumor suppressor protein p53 by binding to the p53 transactivation domain. The p53 gene is inactivated in many human tumors either by mutations or by binding to oncogenic proteins. In some tumors, such as soft tissue sarcomas, overexpression of MDM2 inactivates an otherwise intact p53, disabling the genome integrity checkpoint and allowing cell cycle progression of defective cells. Disruption of the MDM2/p53 interaction leads to increased p53 levels and restored p53 transcriptional activity, indicating restoration of the genome integrity check and therapeutic potential for MDM2/p53 binding antagonists. Here, we show by multidimensional NMR spectroscopy that chalcones (1,3-diphenyl-2-propen-1-ones) are MDM2 inhibitors that bind to a subsite of the p53 binding cleft of human MDM2. Biochemical experiments showed that these compounds can disrupt the MDM2/p53 protein complex, releasing p53 from both the p53/MDM2 and DNA-bound p53/MDM2 complexes. These results thus offer a starting basis for structure-based drug design of cancer therapeutics.
authors.affiliation: Max Planck Institute of Biochemistry, D-82152 Martinsried, Germany.
authors.forename: R
authors.initials: R
authors.lastname: Stoll
authors.forename: C
authors.initials: C
authors.lastname: Renner
authors.forename: S
authors.initials: S
authors.lastname: Hansen
authors.forename: S
authors.initials: S
authors.lastname: Palme
authors.forename: C
authors.initials: C
authors.lastname: Klein
authors.forename: A
authors.initials: A
authors.lastname: Belling
authors.forename: W
authors.initials: W
authors.lastname: Zeslawski
authors.forename: M
authors.initials: M
authors.lastname: Kamionka
authors.forename: T
authors.initials: T
authors.lastname: Rehm
authors.forename: P
authors.initials: P
authors.lastname: Mühlhahn
authors.forename: R
authors.initials: R
authors.lastname: Schumacher
authors.forename: F
authors.initials: F
authors.lastname: Hesse
authors.forename: B
authors.initials: B
authors.lastname: Kaluza
authors.forename: W
authors.initials: W
authors.lastname: Voelter
authors.forename: R A
authors.initials: RA
authors.lastname: Engh
authors.forename: T A
authors.initials: TA
authors.lastname: Holak
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects; D002599:Chalcone / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology*; D004247:DNA / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008958:Models, Molecular; D019906:Nuclear Magnetic Resonance, Biomolecular; D009687:Nuclear Proteins; D011485:Protein Binding / Q000187:drug effects; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D051736:Proto-Oncogene Proteins c-mdm2; D014364:Tryptophan / Q000378:metabolism; D016159:Tumor Suppressor Protein p53 / Q000037:antagonists & inhibitors* / Q000378:metabolism*
chemical_list: D000970:Antineoplastic Agents; D009687:Nuclear Proteins; D011518:Proto-Oncogene Proteins; D016159:Tumor Suppressor Protein p53; D002599:Chalcone; D014364:Tryptophan; D004247:DNA; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2